financetom
Business
financetom
/
Business
/
Comcast Expands High-Speed Internet To Communities In Southeast Georgia: Details
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Comcast Expands High-Speed Internet To Communities In Southeast Georgia: Details
Mar 20, 2025 10:28 AM

Shares of mass media company Comcast ( CMCSA ) Corp are trading higher on Thursday.

The company has effectively connected close to 6,700 residences and businesses across Southeast Georgia, covering towns such as Mt. Vernon, Wrightsville, Soperton, Adrian, Glenwood, and Alamo, to its high-speed Internet network.

This expansion is a major move to enhance the region’s digital infrastructure, offering dependable Internet, mobile, and security services for the first time.

“We are thrilled to extend our network to Mt. Vernon, Wrightsville, Soperton, Adrian, Glenwood, and Alamo, providing residents and businesses with the digital connectivity they need to thrive in today’s technology-driven world,” said Mike McArdle, Regional Senior Vice President.

Also Read: Nvidia Acquires Synthetic Data Firm Gretel To Train AI Models: Report

The goal of this network growth is to drive economic development and assist local businesses and residents in an increasingly digital environment with multi-gigabit Internet and secure connectivity to underserved areas.

Comcast ( CMCSA ) is launching its services through the Xfinity and NOW brands in the regions, providing products such as Internet, mobile, voice, video, and home security.

Comcast Business is strengthening the local workforce by providing a wide array of connectivity solutions designed for businesses, including networking, cybersecurity, and managed services.

Over the past three years, Comcast ( CMCSA ) has invested nearly $47.9 million into over 70 Georgia-based nonprofit organizations, helping people build digital skills and bridging the digital divide.

For the fourth-quarter, the company reported revenue growth of 2.1% year-over-year to $31.92 billion, beating the estimate of $31.64 billion.

Price Action: CMCSA shares traded higher by 1.03% at $36.46 at last check Thursday.

Read Next:

Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
Jun 13, 2025
07:45 AM EDT, 06/13/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said updated results from 17 patients in its phase 1/2 BEACON trial evaluating BEAM-101, a base-editing therapy for severe sickle cell disease, showed robust and durable increases in fetal hemoglobin, reduced sickle hemoglobin, and normalized hemolysis markers. The company will present the new safety and efficacy data at...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Arvinas ( ARVN ) said Friday that its experimental ARV-393 showed significant single-agent activity in a certain type of cell lymphoma, based on data from preclinical studies. The results cover activity in patient-derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. When combined with oral...
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema
Jun 13, 2025
08:00 AM EDT, 06/13/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Friday that initial results from its ongoing long-term open-label trial of navenibart in hereditary angioedema showed a significant reduction in monthly attack rates, supporting the potential for dosing schedules of every three or six months. The biopharmaceutical company said navenibart demonstrated an overall attack-freedom of 50% over...
Copyright 2023-2026 - www.financetom.com All Rights Reserved